A phase IIa proof-of-concept randomized, double-blind, multiple-dose, placebo-controlled clinical study with SB010 in patients with moderate to severe asthma
Latest Information Update: 27 Jan 2022
At a glance
- Drugs Anti-GATA3 gene-therapy (Primary)
- Indications Asthma
- Focus Proof of concept; Therapeutic Use
- Acronyms GIANT-1
- 14 Dec 2021 According to a sterna biologicals media release, results are expected in late 2022/early 2023.
- 14 Dec 2021 According to a sterna biologicals media release, Prof. Dr. med. Tobias Welte is the coordinating investigator for this trial.
- 14 Dec 2021 Status changed from planning to recruiting, according to a sterna biologicals media release.